Atopix Therapeutics Limited is a clinical stage biotechnology company developing novel treatments for Th2-mediated eosinophilic asthma. The company is developing a novel class of oral anti-Th2 therapies, called CRTH2 antagonists. Our lead candidate, OC459, is currently being studied in a Phase 2 proof-of-concept study to evaluate the effect of OC459 in patients with severe asthma who have persistent airway eosinophilia, despite treatment with high doses of inhaled corticosteroids; and a Phase 2a study of the response of asthmatics treated with OC459 to rhinovirus infection (common cold); and a Phase 3 clinical trial of patients with moderate persistent eosinophilic asthma in Russia. Our second cadidate, ATX2417, is undergoing a Phase 1 human safety study.
Type
Private
HQ
Milton, GB
Founded
2012
Atopix was founded in 2012 and is headquartered in Milton, GB
Report incorrect company information

Atopix Office Locations

Atopix has an office in Milton
Milton, GB (HQ)
Milton Park Innovation Centre 99 Park Dr
Show all (1)
Report incorrect company information

Atopix Financials and Metrics

Summary Metrics

Founding Date

2012

Total Funding

$5.1 m

Latest funding size

$5.07 m

Time since last funding

3 years ago

Investors

Atopix's latest funding round in July 2015 was reported to be $5.1 m. In total, Atopix has raised $5.1 m
Show all financial metrics

Atopix Financials

Atopix's revenue was reported to be £453.37 k in FY, 2017
GBP

Revenue (FY, 2017)

453.4 k

Net income (FY, 2017)

592.1 k

EBITDA (FY, 2017)

591.5 k

EBIT (FY, 2017)

587.7 k

Cash (31-Dec-2017)

483
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

225.3 k626.7 k316 k453.4 k

Revenue growth, %

178%(50%)

Operating expense total

2 m2.9 m4.8 m(134.3 k)

EBITDA

(1.8 m)(2.3 m)(4.5 m)(3.3 m)591.5 k
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

1.9 m2.5 m1.3 m431.3 k483

Accounts Receivable

260 80 109

Current Assets

2.4 m3.1 m2.2 m783.2 k725.2 k

PP&E

64 64 6.3 k3 k3.9 k
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(2.1 m)(2.5 m)(4.7 m)(3.4 m)592.1 k

Cash From Operating Activities

(1.8 m)

Cash From Financing Activities

3.7 m

Net Change in Cash

1.9 m
GBPY, 2017

Financial Leverage

-0.3 x
Show all financial metrics
Report incorrect company information